West Pharmaceutical Services, Inc. with ticker code (WST) now have 8 market analysts covering the stock. The analyst consensus now points to a rating of ‘buy’. The target price High/Low ranges between 420 and 325 with the average target price sitting at $383.63. Given that the stocks previous close was at $394.74 this now indicates there is a potential downside of -2.8%. It’s also worth noting that there is a 50 day moving average of $371.97 and the 200 day MA is $311.88. The market cap for the company is 29.69B. The stock price for the company is currently is currently 399.89 USD
The potential market cap would be $28,853,278,409 based on the market consensus.
The company is not paying dividends at this time.
Other points of data to note are a P/E ratio of 54.93, revenue per share of 38.52 and a 12.49% return on assets.
West Pharmaceutical Services, Inc. is a global manufacturer that is engaged in the design and production of technologically advanced, integrated containment and delivery systems for injectable drugs and healthcare products. The Company operates through two segments: Proprietary Products and Contract-Manufactured Products. The Proprietary Products segment offers proprietary packaging, containment solutions, and drug delivery products, along with analytical lab services and other integrated services and solutions, primarily to biologic, generic and pharmaceutical drug customers. The Contract-Manufactured Products segment serves as a fully integrated business, focused on the design, manufacture, and automated assembly of complex devices, primarily for pharmaceutical, diagnostic, and medical device customers. This segment manufactures customer-owned components and devices used in surgical, diagnostic, ophthalmic, injectable, and other drug delivery systems, as well as consumer products.
